Similarly, a combination therapy approach, using VE-821 and KU-55933, significantly decreases the survival of MM cells while inhibition of other NHEJ components (i.e., DNA-PK), does not exert any cytotoxic effects on the viability of MM cells [218]. The gene discussed is PRKDC; the disease is Miyoshi myopathy.